The possible association between DAA treatment for HCV infection and HCC recurrence

Gastroenterology and Hepatology

Volumn 12, Issue 12, 2016, Pages 776-779

  Brown, Robert S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; RIBAVIRIN; UNCLASSIFIED DRUG;

BLOOD TOXICITY; CHEMOEMBOLIZATION; CHRONIC HEPATITIS C; COMORBIDITY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER REGENERATION; LIVER RESECTION; NONALCOHOLIC FATTY LIVER; NOTE; TUMOR ABLATION; TUMOR RECURRENCE;

EID: 85007008103     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. ANRS Collaborative Study Group on Hepatocellular Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016; 65(4): 734-740.
2. Buonfigioli F, Conti F, Andreone P, et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Presented at the European Association for the Study of the Liver meeting; April 13-17, 2016; Barcelona, Spain. Abstract LBP506.
3. Nault JC, Colombo M. Hepatocellular carcinoma and direct-acting antiviral treatments: controversy after the revolution. J Hepatol. 2016; 65(4): 663-665.
4. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65(4): 719-726.
5. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016; 65(4): 859-860.